Please use this identifier to cite or link to this item:
https://doi.org/10.3389/fphar.2018.01125
DC Field | Value | |
---|---|---|
dc.title | N-substituted pyrido-1,4-Oxazin-3-ones induce apoptosis of hepatocellular carcinoma cells by targeting NF-?B signaling pathway | |
dc.contributor.author | Mohan, C.D | |
dc.contributor.author | Bharathkumar, H | |
dc.contributor.author | Dukanya, Department of Studies in Organic Chemistry, University of Mysore, Mysore, India | |
dc.contributor.author | Rangappa, S | |
dc.contributor.author | Shanmugam, M.K | |
dc.contributor.author | Chinnathambi, A | |
dc.contributor.author | Alharbi, S.A | |
dc.contributor.author | Alahmadi, T.A | |
dc.contributor.author | Bhattacharjee, A | |
dc.contributor.author | Lobie, P.E | |
dc.contributor.author | Deivasigamani, A | |
dc.contributor.author | Hui, K.M | |
dc.contributor.author | Sethi, G | |
dc.contributor.author | Basappa, Laboratory of Chemical Biology, Department of Chemistry, Bangalore University, Bangalore, India, Department of Studies in Organic Chemistry, University of Mysore, Mysore, India | |
dc.contributor.author | Rangappa, K.S | |
dc.contributor.author | Kumar, A.P | |
dc.date.accessioned | 2020-10-27T10:04:52Z | |
dc.date.available | 2020-10-27T10:04:52Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Mohan, C.D, Bharathkumar, H, Dukanya, Department of Studies in Organic Chemistry, University of Mysore, Mysore, India, Rangappa, S, Shanmugam, M.K, Chinnathambi, A, Alharbi, S.A, Alahmadi, T.A, Bhattacharjee, A, Lobie, P.E, Deivasigamani, A, Hui, K.M, Sethi, G, Basappa, Laboratory of Chemical Biology, Department of Chemistry, Bangalore University, Bangalore, India, Department of Studies in Organic Chemistry, University of Mysore, Mysore, India, Rangappa, K.S, Kumar, A.P (2018). N-substituted pyrido-1,4-Oxazin-3-ones induce apoptosis of hepatocellular carcinoma cells by targeting NF-?B signaling pathway. Frontiers in Pharmacology 9 (NOV) : 1125. ScholarBank@NUS Repository. https://doi.org/10.3389/fphar.2018.01125 | |
dc.identifier.issn | 16639812 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/181171 | |
dc.description.abstract | Hepatocellular carcinoma (HCC) is a fatal disease and ranked fifth in cancer related mortality. Persistent activation of NF-?B is responsible for the oncogenesis, metastasis, tumor evasion, anti-apoptosis, angiogenesis and proliferation in HCC. Therefore, designing of chemically novel, biologically potent small molecules that target NF-?B signaling cascade have gained prominent clinical interest. Herein we synthesized a novel class of 4-(substituted)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one by reacting 2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one with various alkyl halides by using combustion derived bismuth oxide. We evaluated the antiproliferative efficacy of newly synthesized compounds against HCC cells and identified 4-(4-nitrobenzyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one (NPO) as lead anticancer agent. In addition, we investigated the effect of NPO on the DNA binding ability of NF-?B and NF-?B regulated luciferase expression in HCC cells. The results demonstrated that NPO can induce significant growth inhibitory effects in HepG2, HCCLM3 and Huh-7 cells in dose and time-dependent manner. Interestingly, NPO induced significant downregulation in p65 DNA binding ability, p65 phosphorylation and subsequent expression of NF-?B dependent luciferase gene expression in diverse HCC cell lines. Further, in silico docking analysis suggested that NPO can show direct physical interaction with NF-?B. Finally, NPO was found to significantly abrogate tumor growth at a dose of 50 mg/kg in an orthotopic mouse model. Thus, we report the potential anticancer effects of NPO as a novel inhibitor of NF-?B signaling pathway in HCC. Copyright © 2018 Mohan, Bharathkumar, Dukanya, Rangappa, Shanmugam. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | 2 [3 (3 oxo 2h pyrido[3,2 b][1,4]oxazin 4(3h) yl)propyl]isoindoline 1,3 dione | |
dc.subject | 4 (2,6 dichlorobenzyl) 2h pyrido[3,2 b][1,4]oxazin 3(4h) one | |
dc.subject | 4 (4 isopropylbenzyl) 2h pyrido[3,2 b][1,4]oxazin 3(4h) one | |
dc.subject | 4 (4 nitrobenzyl) 2h pyrido [3,2 b][1,4]oxazin 3(4h) one | |
dc.subject | 4 (cyclohexylmethyl) 2h pyrido[3,2 b][1,4]oxazin 3(4h) one | |
dc.subject | 4 [(3 oxo 2h pyrido[3,2 b][1,4]oxazin 4(3h) yl)methyl]benzonitrile | |
dc.subject | 4 [(6,6 dimethyl 4 phenyl 5,6 dihydro 4h 1,2 oxazin 3 yl)methyl] 2h pyrido[3,2 b][1,4]oxazin 3(4h) one | |
dc.subject | 4 [4 (tert butyl)benzyl] 2h pyrido[3,2 b][1,4]oxazin 3(4h) one | |
dc.subject | 4 [[4 (4 chlorophenyl) 6,6 dimethyl 5,6 dihydro 4h 1,2 oxazin 3 yl]methyl] 2h pyrido[3,2 b][1,4]oxazin 3(4h) one | |
dc.subject | 4' [(3 oxo 2h pyrido[3,2 b][1,4]oxazin 4(3H) yl)methyl] [1,10 biphenyl] 2 carbonitrile | |
dc.subject | antineoplastic agent | |
dc.subject | DNA | |
dc.subject | immunoglobulin enhancer binding protein | |
dc.subject | liver protective agent | |
dc.subject | luciferase | |
dc.subject | transcription factor RelA | |
dc.subject | unclassified drug | |
dc.subject | animal experiment | |
dc.subject | animal model | |
dc.subject | animal tissue | |
dc.subject | antiproliferative activity | |
dc.subject | apoptosis | |
dc.subject | Article | |
dc.subject | cancer inhibition | |
dc.subject | cell viability | |
dc.subject | computer model | |
dc.subject | controlled study | |
dc.subject | dose response | |
dc.subject | down regulation | |
dc.subject | drug effect | |
dc.subject | drug efficacy | |
dc.subject | drug identification | |
dc.subject | drug potency | |
dc.subject | drug synthesis | |
dc.subject | female | |
dc.subject | gene expression regulation | |
dc.subject | HCCLM3 cell line | |
dc.subject | Hep-G2 cell line | |
dc.subject | Huh-7 cell line | |
dc.subject | IC50 | |
dc.subject | liver cell carcinoma | |
dc.subject | luciferase gene | |
dc.subject | molecularly targeted therapy | |
dc.subject | mouse | |
dc.subject | nonhuman | |
dc.subject | pharmacological parameters | |
dc.subject | protein DNA binding | |
dc.subject | protein expression | |
dc.subject | protein phosphorylation | |
dc.subject | time dependence | |
dc.subject | tumor volume | |
dc.type | Article | |
dc.contributor.department | PHARMACOLOGY | |
dc.description.doi | 10.3389/fphar.2018.01125 | |
dc.description.sourcetitle | Frontiers in Pharmacology | |
dc.description.volume | 9 | |
dc.description.issue | NOV | |
dc.description.page | 1125 | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3389_fphar_2018_01125.pdf | 4.56 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License